| 孙慧,张莎莎,温晓红,吴勤美,陶爱伟,周华.祛风抗敏煎联合依巴斯汀治疗慢性荨麻疹临床观察[J].浙江中西医结合杂志,2015,25(3): |
| 祛风抗敏煎联合依巴斯汀治疗慢性荨麻疹临床观察 |
| Clinical Observation of Patients with Chronic Urticaria under the Treatment of Combined Therapy of qufengkangminjian and Ebastine Tablets |
| 投稿时间：2014-08-17 修订日期：2015-01-16 |
| DOI： |
| 中文关键词: 慢性荨麻疹 祛风抗敏煎 依巴斯汀片 临床观察 |
| 英文关键词:Chronic Urticaria qufengkangminjian Ebastine Tablet Clinical Research |
| 基金项目:2013年浙江省中医药科学研究基金计划“祛风抗敏煎与依巴斯汀治疗慢性荨麻疹的临床试验研究”（项目编号：2013ZB127） |
|
| 摘要点击次数: 802 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 观察中药汤剂祛风抗敏煎联合西药依巴斯汀治疗慢性荨麻疹的临床疗效。方法 将皮肤科门诊符合纳入标准的240例患者随机分为中西医结合治疗组(120例,剔除2例)和单纯西药对照组(120例,剔除4例),疗程为8周,分别于治疗前、治疗2周、4周、6周、8周、停药4周后据临床观察表来评定积分,根据统计学来分析积分下降指数、复发率等情况,并观察血清总IgE水平、嗜酸性粒细胞计数在治疗前后的水平变化。结果 ①治疗组总有效率为88.13%,对照组为80.17%,组间比较差异不明显(P>0.05)。②观察治疗前与治疗后皮损症候积分,在瘙痒程度、皮损分布、发作频率以及皮肤划痕症这四项指标上,两组间比较均具有显著性差异(P <0.05)。其他三项指标组间比较差异不明显(P >0.05)。③治疗前后两组内血清总IgE水平比较,有显著性差异(P <0.05)；组间比较差异不明显(P >0.05)。④治疗前后两组内及组间血嗜酸性粒细胞计数比较,均有显著性差异(P <0.05)。⑤停药4周后随访发现治疗组复发率(12.71%)与对照组(35.35%)比较有显著差异(P <0.05)。结论 中药汤剂祛风抗敏煎联合西药依巴斯汀方法对慢性荨麻疹临床疗效确切,复发率低,安全可靠,值得临床推广。 |
| 英文摘要: |
| Objective To observe the clinical effect of combined therapy of qufengkangminjian and Ebastine tablets (ET) on Chronic urticaria (CU). Methods 240 patients were randomly divided into the treatment group (120 patients) and the control group (120 patients), in which patients received the usual treatment of ET, and combined therapy of qufengkangminjian and ET individually for 8 weeks. Effect was respectively observed on 2th, 4th, 6th and 8th week. Relapse rates were recorded in 4 weeks after treatment. Serum total IgE and eosinophil count (EOS) were measured before and after treatment. Results Efficient rates of treatment group and control group were 88.13% and 80.17% respectively. There was not significantly statistical difference between two groups (P >0.05). But treatment group can drop the level of serum IgE and EOS. Relapse rates in two groups were 15.56% and 31.25% respectively. There was significantly statistical difference between two groups (P <0.05). Conclusion Combined therapy of qufengkangminjian and ET have high clinical efficacy and safety in treatment of CU . |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
